Compare KUST & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KUST | REVB |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.9M |
| IPO Year | 2018 | 2020 |
| Metric | KUST | REVB |
|---|---|---|
| Price | $3.27 | $3.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $124.25 |
| AVG Volume (30 Days) | 13.6K | ★ 64.7K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.68 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,577,600.00 | N/A |
| Revenue This Year | $40.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.97 | $0.44 |
| 52 Week High | $224.00 | $4.75 |
| Indicator | KUST | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 65.12 |
| Support Level | N/A | $0.97 |
| Resistance Level | $4.13 | $4.06 |
| Average True Range (ATR) | 0.33 | 0.36 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 20.69 | 27.56 |
Kustom Entertainment Inc provides live event production and ticketing technology services. The company operates in two segments: video solutions and entertainment. The Video Solutions Segment represents the Company's legacy operations and includes the development, manufacture, and sale of digital video imaging and storage products, disinfectant, and related safety products for use in law enforcement, security, and commercial applications. The Entertainment Segment operates a secondary ticketing platform through TicketSmarter.com, acting as an intermediary between ticket buyers and sellers. In addition, this segment includes live event production and promotion activities, including the Country Stampede music festival and other entertainment events.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.